TerminatedNCT02398500
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
PHASE1 · PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- June 5, 2019
Registry Intervention View
Ranibizumab 0.5 mg
Trial registrations containing the exact intervention label Ranibizumab 0.5 mg.
Exact registry label · Not reported
6 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
5 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT02130024
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
PHASE4 · 281 planned enrolment
- Countries listed
- 1
- Registry update
- June 5, 2019
CompletedNCT02257632
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
PHASE4 · 41 planned enrolment
- Countries listed
- 1
- Registry update
- May 7, 2019
CompletedNCT00379795
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
Phase not reported · 853 planned enrolment
- Countries listed
- 0
- Registry update
- May 11, 2017
CompletedNCT01304693
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
PHASE1 · PHASE2 · 376 planned enrolment
- Countries listed
- 0
- Registry update
- July 17, 2014
CompletedNCT01148511
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
PHASE4 · 99 planned enrolment
- Countries listed
- 1
- Registry update
- May 30, 2013